

The Use Of Glucagon In The Treatment Of Hypoglycaemia Due To Congenital Hyperinsulinism

C Jadawji, M S Estebanez, R Padidela, L Bowden, L Rigby, J Kinzell, K E Cosgrove, M J Dunne, I Banerjee

Background

- · Congenital Hyperinsulinism (CHI) can cause severe hypoglycaemia with consequent adverse neurodevelopment
- Continuous Glucagon Infusion (CGI) has been utilised to achieve glycaemic stability its efficacy has not been systematically reported

Aims

• To review the efficacy of CGI and assess the complications associated with glucagon infusion

Methods

- A retrospective review was conducted, in a cohort of 31 children over a 5 year period
- The efficacy of CGI was reviewed by assessing the impact on the glucose infusion rate (GIR) within 48 hours of treatment

• Factors affecting severity of CHI: K-ATP channel gene mutations, diazoxide unresponsiveness, requirement for second-line treatment with octreotide and sub-total pancreatectomy were also assessed in relation to CGI

Results

- \bullet CGI in a dose of 5 mcg/kg/hour administered either intravenously (n=29) or subcutaneously (n=2) reduced GIR from a mean (interquartile range) of 15.9 (8.1) to 11.5 (4.9) mg/kg/minute. See Fig. 1
- Reduction independent of factors affecting the severity of CHI
- Maximum dose required to achieve euglycaemia [12.4 (15) mcg/kg/hour] was directly correlated with the pre-glucagon GIR [R^2 =0.7, p<0.001]
- Duration of 33 (30) days of CGI helped maintaining euglycaemia in addition to therapy with diazoxide or octreotide [n=16]



Complications

- 1 patient developed a necrolytic migratory erythema (NME) Resolved once CGI discontinued. Refer to Fig. 2
- Crystallization of glucagon can lead to line obstruction, though not reported in this study

Fig. 2: Images depicting NME after administration of subcutaneous CGI





- · CGI is effective in reducing GIR in patients with CHI in the short and long term management
- Generally safe, NME is a possible adverse event with CGI treatment